FRANKFURT: BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb (NYSE: BMY) announced Monday a global collaboration to co-develop and co-commercialize BioNTech’s experimental bispecific antibody, BNT327, for treating solid tumors. The partnership aims to accelerate the development of BNT327, which targets PD-L1 and VEGF-A, two…
NEW YORK: BioNTech and Pfizer have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants, which also allows for the…
NEW YORK: Pfizer Inc. and BioNTech SE announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2….